StockWatch
·

ReposiTrak, Inc. Q3 FY26 Results

TRAKQ3 FY26 Results
Filing
MetricValue ($ M)Q2 FY26Q3 FY25
Revenue5.880.3%0.5%
Total Income5.880.3%0.5%
Expenditure3.6310.2%11.5%
PBT2.4414.0%15.1%
Net Profit1.9917.8%1.0%
OPM38.27%7.24pp7.68pp
NPM33.75%4.96pp0.51pp
EPS0.1122.2%10.0%
View full financials

ReposiTrak Reports Q3 FY26: Operating Income Up 24%, EPS $0.10

18 May 2026 · 18 May, 11:16 pm

Summary

ReposiTrak reported flat revenue of $5.9 million for the third quarter of fiscal 2026 compared to the prior year. However, operating income increased by 24% to $2.3 million, and GAAP net income increased by 1% to $2.0 million. Year-to-date revenue increased by 5% to $17.7 million, with operating income up 28% to $6.0 million. The company ended the quarter with $26.4 million in cash and no bank debt, generating $5.9 million in cash from operations for the first nine months of fiscal 2026.

Key Highlights

  1. 1

    ReposiTrak's third quarter total revenue was $5.9 million, essentially flat year-over-year.

  2. 2

    Operating income increased 24% to $2.3 million for the third quarter.

  3. 3

    GAAP net income increased 1% to $2.0 million in the third quarter.

  4. 4

    Fiscal year-to-date revenue increased 5% year-over-year to $17.7 million.

  5. 5

    Operating income increased 28% to $6.0 million for the first nine months of fiscal 2026.

  6. 6

    The Company generated $5.9 million in cash from operations for the first nine months of fiscal 2026.

  7. 7

    The Company finished the period with $26.4 million in cash and no bank debt.

Management Comments

R

Randall K. Fields

"The FDA's traceability initiative has effectively erased the lines between our disparate product offerings. What were once distinct business lines increasingly operate as a single, comprehensive food safety platform, a solution that is unrivaled in the industry. That convergence is a meaningful strategic advantage, because no one else delivers all of these capabilities in a single platform. This creates advantages in cross-selling across all layers of the industry, from growers to suppliers, wholesalers and retailers." "During the quarter, we filed two patent applications covering our Touchless Traceability™ solution, creating a durable competitive moat around the only approach that delivers FDA-compliant traceability at scale,” added Mr. Fields. “With deployments already in production at a leading grocer and a major Southern wholesaler, Touchless Traceability is establishing a new standard for accuracy and efficiency. These two customers are the only two companies in the world we are aware of that can track products from the supplier to their distribution center to their retail stores without ever having to touch or scan the product." "Our collaboration with SPAR Group pairs our ability to identify supply chain and merchandising issues with SPAR's field execution, giving retailers a true end-to-end solution from problem identification to in-store resolution,” concluded Mr. Fields. “This is the next evolution of our platform: from insight to action. We believe this collaboration has the potential to be significant not only to our respective businesses, but to the industry as a whole."

J

John Merrill

As we close out the third quarter of fiscal 2026 and head into the final quarter of the fiscal year, I want to spend a few minutes reinforcing the long-term framework that continues to guide our execution, operating discipline, and capital allocation strategy. At ReposiTrak, our strategy has remained disciplined and consistent. We've remained focused on building a highly scalable SaaS platform characterized by recurring revenue, expanding operating margins, cash flow generation, and a conservatively capitalized balance sheet. At the same time, we have maintained a balanced approach towards reinvestment, innovation, and direct shareholder returns. I believe our results demonstrate the strength and consistency of that operating framework.

Informational and educational content only. Not investment advice.